Latest News About Replimune

Here’s the latest on Replimune based on recent publicly reported updates.

• FDA action: Replimune received a second Complete Response Letter (CRL) for RP1 in combination with nivolumab for advanced melanoma, signaling that the agency still views the data as insufficient for approval. This has pressured the stock and the company’s near-term development plan. The response underscores ongoing regulatory hurdles despite earlier IGNYTE trial signals.[3][9][10]

• Company updates and regulatory path: The company has been engaging with the FDA, including a Type A meeting in 2025 to discuss the CRL and potential next steps, with discussions around accelerated approval pathways and a possible resubmission plan for RP1. In parallel, there’s ongoing consideration of strategic adjustments in manufacturing and clinical development in light of the CRL.[1][4]

• Clinical program status: RP1 remains the lead program, with ongoing global Phase 3 IGNYTE-3 evaluating RP1 with nivolumab in advanced melanoma patients who progressed on prior anti-PD-1/anti-CTLA-4 therapy or are ineligible for CTLA-4 treatment; results remain pivotal for any potential alternative regulatory pathway. RP2 programs in hepatocellular carcinoma and biliary tract cancer are separate initiatives, under collaboration with Roche, with data readouts anticipated through 2026.[2]

• Market and media coverage: Replimune’s situation has attracted broad coverage, including financial and mainstream outlets, noting investor reactions to the FDA decisions and the company’s stated plans to work with regulators to determine a path forward. CNBC discussions have highlighted leadership perspectives on next steps after regulatory setbacks.[6][10]

• Historical context: Earlier topline IGNYTE results showed objective responses and duration of response for RP1 plus nivolumab, which informed some enthusiasm but did not translate into an FDA approval at that time; the CRL commentary notes that the agency did not find substantial evidence of effectiveness based on the submitted data.[9][3]

Illustration: If you’re tracking this program, a simple timeline would look like:

• 2024–2025: IGNYTE trial data presented; early signs of activity.
• 2025: Type A FDA meeting to discuss CRL feedback; ongoing discussions with FDA.
• 2026: Second CRL issued; regulatory path under reconsideration; potential resubmission or alternative paths under exploration.

If you’d like, I can pull more precise quotes from the FDA correspondence and construct a concise timeline with citation links, or summarize how investors are Reacting in the markets right now.

Citations:

• Replimune FDA CRL and regulatory updates[4][10][1][9]
• IGNYTE trial data and RP1 program status[2][3]
• Market reaction and media coverage[10][6]